Dustin Kliner
Interventional Cardiology · Pittsburgh, PANPI 1043407802
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (37.5%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Abbott at 53.4% of the total.
Across 486 payments — averaging $150.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$39K
- Medtronic$29K
- Boston Scientific$1K
- Novartis$609
- Shockwave Medical, Inc$605
- Edwards Lifesciences$554
- plus $2K from 19 others
Across 8 payments — averaging $2522.75 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$20K
What the payments were for
- Consulting fees$9,87513%
- Speaking & faculty fees$27,42537%
- Travel & lodging$21,36629%
- Food & beverage$14,16619%
- Entertainment$1040%
- Other$2820%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 151 | $39,110 |
| Medtronic(2 entities) | 207 | $29,071 |
| Boston Scientific | 15 | $1,461 |
| Novartis | 46 | $609 |
| Shockwave Medical, Inc | 6 | $605 |
| Edwards Lifesciences | 12 | $554 |
| Abiomed | 6 | $433 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $216 |
| Inari Medical, Inc. | 1 | $184 |
| Johnson & Johnson | 5 | $183 |
| Terumo Medical Corporation | 2 | $116 |
| Stryker | 2 | $111 |
| Opsens Inc. | 1 | $104 |
| Amgen | 5 | $90 |
| Kestra Medical Technology Services, Inc. | 3 | $72 |
| Atricure, Inc. | 2 | $61 |
| E.r. Squibb & Sons, L.L.C. | 3 | $54 |
| Pfizer | 3 | $45 |
| Cardiovascular Systems Inc. | 2 | $35 |
| Amarin Pharma, Inc. | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Novo Nordisk | 1 | $18 |
| Heartflow, Inc. | 1 | $16 |
| AstraZeneca | 1 | $15 |
| Cardiva Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NAVITOR$28,879
- COREVALVE EVOLUT R$14,553
- CoreValve Evolut$10,646
- PORTICO$6,236
- AMPLATZER TALISMAN$1,250
- VersaCross Access Solution$620
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$237
- FLOWTRIEVER CATHETER, S$184
- CT THROMBECTOMY SYSTEM KIT$184
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$182
- AMPLATZER AMULET$149
- ABSOLUTE PRO$135
- GENERAL - THERAPIES$131
- XARELTO$115
- Impella$107
- GENERAL - STENTS$106
- OptoWire$104
- Watchman$102
- Portico Transcatheter Aortic Heart Valve$102
How this compares
$73,218 in reported general payments places this provider in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
See all interventional cardiology providers in Pennsylvania →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 411 | $420,846 |
| EntrestoSacubitril/Valsartan | 234 | $249,477 |
| Repatha SureclickEvolocumab | 101 | $99,650 |
| XareltoRivaroxaban | 64 | $89,259 |
| JardianceEmpagliflozin | 43 | $57,749 |
| Praluent PenAlirocumab | 26 | $24,240 |
| FarxigaDapagliflozin Propanediol | 17 | $22,110 |
| Rosuvastatin Calcium | 981 | $16,394 |
| Valsartan | 342 | $12,543 |
| Carvedilol | 972 | $10,232 |
| Bisoprolol Fumarate | 248 | $9,637 |
| Losartan Potassium | 480 | $7,074 |
| Nifedipine ErNifedipine | 211 | $6,573 |
| Atorvastatin Calcium | 448 | $6,322 |
| Spironolactone | 486 | $5,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $45 | $420,846411 claims |
| NovartisEntresto | $609 | $249,477234 claims |
| Johnson & JohnsonXarelto | $183 | $89,25964 claims |
| AstraZenecaFarxiga | $15 | $22,11017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 281 interventional cardiology providers in Pennsylvania.
Other interventional cardiology in Pittsburgh
- David LasordaPittsburgh$271K
- Ramzi KhalilPittsburgh$217K
- Ryan ZuzekPittsburgh$152K
- Catalin TomaPittsburgh$120K
- Adnan KhalifPittsburgh$39K
- Saad TabbaraPittsburgh$28K
- Jeffrey FowlerPittsburgh$26K
- Marinos CharalambousPittsburgh$25K
- Nishant SethiScranton$1.3M
- Matthew BeckerErie$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.